US Patent 10,780,088: Talazoparib Prostate-Cancer Patent Scope and Landscape
US Patent No. 10,780,088 protects methods of treating prostate cancer with talazoparib, including its specific (8S,9R) stereoisomer, alone or with radiation and specified anticancer agents. The patent is method-of-use focused. It does not claim talazoparib as a chemical compound, a dosage form, a manufacturing process, or a particular dosing regimen.
What drug does US Patent 10,780,088 cover?
The claimed compound is talazoparib, also known as BMN 673 and PF-06944076. Its systematic name is:
5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one.
Talazoparib is an orally administered PARP inhibitor marketed by Pfizer as Talzenna. The drug inhibits PARP1 and PARP2 catalytic activity and traps PARP-DNA complexes. The FDA has approved Talzenna for certain breast-cancer and metastatic castration-resistant prostate-cancer populations, with the prostate-cancer indication used in combination with enzalutamide.[1]
Core patent information
| Item |
Information |
| U.S. patent |
US 10,780,088 B2 |
| Patent type |
Therapeutic method-of-use patent |
| Covered active ingredient |
Talazoparib |
| Principal disease |
Prostate cancer |
| Covered administration |
Talazoparib alone, with ionizing radiation, or with listed chemotherapy agents |
| Stereochemical scope |
Broad claim 1 plus specific (8S,9R) claim 9 |
| Dosage form claimed |
None |
| Dose claimed |
None |
| Route claimed |
None |
| Biomarker requirement |
None |
| Combination requirement |
Present in dependent claims, not in independent claims |
| Human-treatment claims |
Claims 5-8 and 13-16 |
| Patent status |
Granted U.S. patent; current term and Orange Book listing should be evaluated against the USPTO and FDA records |
What are the independent claims in US 10,780,088?
Claims 1 and 9 are the independent claims.
Claim 1: broad talazoparib prostate-cancer method
Claim 1 covers:
- treating prostate cancer;
- administering a therapeutically effective amount of talazoparib;
- including a pharmaceutically acceptable salt or solvate;
- without requiring radiation, chemotherapy, a biomarker, a particular disease stage, or a particular patient genotype.
The claim uses the compound name without the stereochemical designation. That language is materially broader than claim 9 because it can encompass the claimed molecular form without expressly limiting the claim to the (8S,9R) enantiomer.
A potential infringement theory under claim 1 would arise when a party administers talazoparib to treat prostate cancer, provided the other claim elements are met. The claim does not require that talazoparib be the sole therapy. Combination therapy remains within the scope of claim 1 because the claim does not exclude other treatments.
Claim 9: specific stereochemical method
Claim 9 is directed to treating prostate cancer with:
(8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one, or a pharmaceutically acceptable salt.
Compared with claim 1, claim 9 is narrower because it expressly identifies the (8S,9R) stereoisomer. It does not expressly recite a solvate. A product containing the marketed active stereoisomer would be the principal commercial subject of claim 9.
The distinction between claims 1 and 9 creates two overlapping protection layers:
| Issue |
Claim 1 |
Claim 9 |
| Compound identification |
Talazoparib structure without explicit stereochemical limitation |
Explicit (8S,9R) stereoisomer |
| Salt coverage |
Yes |
Yes |
| Solvate coverage |
Yes |
Not expressly |
| Prostate-cancer treatment |
Yes |
Yes |
| Monotherapy |
Yes |
Yes |
| Combination therapy |
Covered through claim 2 |
Covered through claim 10 |
| Human limitation |
Added in claims 5-8 |
Added in claims 13-16 |
What treatments and combinations are protected?
Claims 2 and 10 extend the independent claims to treatment with ionizing radiation, one or more chemotherapeutic agents, or both.
The combination language is broad. It does not specify:
- the sequence of administration;
- whether the agents must be administered simultaneously;
- dose levels;
- treatment cycles;
- treatment duration;
- radiation dose or fractionation;
- whether talazoparib must be the primary antineoplastic therapy.
Chemotherapy combinations in claims 3 and 11
Claims 3 and 11 list a large group of possible agents and agent classes, including:
- temozolomide;
- dacarbazine;
- irinotecan;
- topotecan;
- doxorubicin;
- platinum agents;
- paclitaxel;
- cetuximab;
- methotrexate;
- hormones;
- antiestrogens;
- antiandrogens;
- gonadotropin-releasing hormone analogs;
- interferons;
- tyrosine kinase inhibitors;
- gefitinib;
- imatinib;
- gemtuzumab; and
- BNP 1350.
The claims use “each chemotherapeutic agent” independently from the listed alternatives. This drafting structure permits treatment with talazoparib plus one or more selected agents, rather than requiring the full list to be administered.
Narrower combinations in claims 4 and 12
Claims 4 and 12 limit the chemotherapy combination to:
- irinotecan;
- cisplatin;
- carboplatin;
- paclitaxel; or
- temozolomide.
These claims provide fallback positions if the broader combination claims are challenged. They also have greater factual clarity because the listed agents are specific compounds rather than broad categories.
Relevance to enzalutamide
Enzalutamide is an androgen-receptor inhibitor and is generally characterized as an antiandrogen. The patent’s claim 3 and claim 11 references to “an antiandrogen” could therefore be relevant to talazoparib-enzalutamide treatment, subject to claim construction and the patent’s specification.
The FDA-approved prostate-cancer Talzenna regimen is talazoparib in combination with enzalutamide for certain patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.[1] The commercial label is narrower than claim 1 because the patent does not require a particular biomarker or disease stage, while the FDA indication does.
How strong is the patent scope?
The strongest commercial feature is the breadth of claim 1. It covers prostate-cancer treatment with talazoparib without a biomarker limitation or combination requirement. A generic or alternative supplier seeking approval for prostate cancer could face a direct method-of-use issue even if its product does not infringe a formulation or composition patent.
Scope strengths
- Claim 1 covers monotherapy and combination treatment.
- The claim does not require a specific prostate-cancer stage.
- The claim does not require metastatic disease or castration resistance.
- The claim does not require a BRCA or other HRR mutation.
- The claim does not limit dose, route, schedule, or formulation.
- Claim 9 separately protects the marketed (8S,9R) stereoisomer.
- Human-use claims provide express commercial-treatment fallbacks.
Scope limitations
- The claims are limited to prostate cancer.
- They do not claim talazoparib for all cancers.
- They do not claim the chemical compound itself.
- They do not claim a capsule, tablet, liquid, or other formulation.
- They do not claim a specific dose or dosing interval.
- The listed combinations may face written-description, enablement, or obviousness challenges if the patent’s disclosure does not support the full breadth.
- Claims 13-16 contain apparent dependency irregularities in the supplied text. Claims 13 and 14 both refer to claim 10, although claim 14 appears intended to narrow a stereochemical branch. The issued patent and certificate-of-correction records control the legally operative language.
The patent is commercially meaningful but should not be treated as a complete barrier to generic entry. The relevant risk depends on the approved label, Orange Book use codes, patent-term adjustments, other listed patents, and whether a generic applicant uses a Paragraph IV certification or a section viii statement.
What patents protect Talzenna beyond US 10,780,088?
Talazoparib protection is expected to involve several patent categories:
| Patent category |
Typical subject matter |
Relevance |
| Composition-of-matter |
Talazoparib molecule and related compounds |
Usually the strongest early barrier |
| Stereochemistry |
Specific active enantiomer |
Protects the commercial drug form |
| Therapeutic methods |
Breast cancer, prostate cancer, and other cancers |
Can block labeled-use entry |
| Combination therapy |
Talazoparib with enzalutamide or other agents |
Relevant to the current prostate-cancer regimen |
| Formulation |
Oral dosage forms, crystalline forms, salts, or excipients |
May extend practical protection |
| Manufacturing |
Processes for producing talazoparib or intermediates |
Can complicate supply but usually does not block a non-infringing process |
| Regulatory exclusivity |
New-drug and supplemental approval exclusivity |
Independent of patent rights |
US 10,780,088 should therefore be analyzed as one layer of the Talzenna estate, not as the entire patent position. The composition patent and any formulation or combination patents may create separate entry risks.
When does US Patent 10,780,088 lose exclusivity?
The patent was granted on September 22, 2020. Its expiration date cannot be determined reliably from the claim text alone because the effective expiration depends on the patent family’s earliest nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
The grant date is not the expiration date. A 20-year term is generally measured from the earliest effective nonprovisional filing date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.[2]
For commercial planning, the relevant date is the later of:
- the patent’s enforceable expiration date;
- any applicable patent-term extension;
- the end of FDA regulatory exclusivity; and
- the expiration of other Orange Book-listed patents that remain relevant to the proposed label.
What is the FDA and Orange Book status of Talzenna?
Talzenna received FDA approval in 2018 for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer after specified prior therapy. The FDA later approved the drug in combination with enzalutamide for adults with HRR gene-mutated metastatic castration-resistant prostate cancer.[1]
Regulatory and commercial relevance
| Issue |
Assessment |
| FDA product |
Talzenna |
| Sponsor |
Pfizer |
| Active ingredient |
Talazoparib |
| Product type |
Small-molecule prescription drug |
| Prostate indication |
Combination with enzalutamide in biomarker-defined mCRPC |
| Regulatory pathway for competitors |
ANDA for generics; 505(b)(2) may be relevant for a different formulation or use |
| Biosimilar pathway |
Not applicable |
| Orange Book relevance |
Patent listings and use codes must be reviewed for the approved Talzenna indications |
| Label carve-out potential |
Possible for omitted patented uses, subject to FDA labeling rules and litigation risk |
Because talazoparib is a small molecule, competitors would pursue an abbreviated new drug application rather than a biosimilar application. The primary regulatory challenge is demonstrating pharmaceutical equivalence and bioequivalence while addressing listed patents through Paragraph I, II, III, or IV certifications.
Which companies are likely to challenge Talazoparib patents?
The most likely challengers are generic manufacturers with oncology portfolios and established ANDA operations. Potential participants in the competitive field include Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy’s, Cipla, and other major U.S. or international generic companies.
A company does not need to challenge every patent in the estate. It may:
- certify Paragraph III to await patent expiry;
- submit a Paragraph IV certification;
- use a section viii statement to omit a patented use;
- challenge only formulation or method patents;
- pursue a 505(b)(2) application with a different dosage form or indication.
No company should be characterized as having filed a Paragraph IV challenge to US 10,780,088 without confirmation from FDA, PACER, or the relevant Abbreviated New Drug Application litigation record.
What generic-entry risks exist?
Scenario 1: Full-label generic entry
A generic seeking the prostate-cancer indication would face the greatest risk because its label could instruct physicians to administer talazoparib for prostate cancer. That label could support induced-infringement allegations under 35 U.S.C. § 271(b).
Scenario 2: Section viii carve-out
A generic could omit prostate-cancer language if the FDA-approved reference label includes other unpatented indications. This strategy may reduce, but not eliminate, risk. Pfizer could argue that marketing, promotional material, product design, or the remaining label still encourages use for the patented indication.
Scenario 3: Paragraph IV challenge
A Paragraph IV challenger could argue that the patent is invalid, unenforceable, or not infringed. Common grounds would include:
- obviousness based on earlier PARP inhibitors and prostate-cancer treatment;
- lack of written description for the broad chemotherapy list;
- lack of enablement across all prostate-cancer populations;
- indefiniteness in “therapeutically effective amount” or combination language;
- noninfringement based on a non-covered use or label;
- lack of patentable distinction between the broad and stereospecific claims.
Scenario 4: Alternative formulation
A competitor could develop a different formulation, but a formulation change would not avoid claims 1 or 9 if the product is still administered to treat prostate cancer with talazoparib. It could avoid separate formulation claims, if any, but not necessarily the method claims.
Does biosimilar risk apply to Talzenna?
No. Talazoparib is a chemically synthesized small molecule. The relevant competitive pathway is generic substitution under the ANDA framework, not biosimilar approval under the Public Health Service Act.
The absence of biosimilar risk does not eliminate market-entry barriers. Generic applicants still must address:
- listed patents;
- use-code accuracy;
- exclusivity periods;
- bioequivalence;
- labeling carve-outs;
- pediatric exclusivity, if applicable; and
- litigation-triggered approval stays.
What geographic protection does the patent provide?
US 10,780,088 provides protection only in the United States. It does not directly block use, sale, manufacture, or importation in Europe, Japan, China, Canada, or other jurisdictions.
A global freedom-to-operate review should map corresponding family members by jurisdiction and separate:
- composition claims;
- prostate-cancer method claims;
- enzalutamide-combination claims;
- formulation claims;
- manufacturing claims; and
- regulatory exclusivity.
U.S. method claims can still affect imported products if the imported product is intended for a use that induces infringement in the United States. Manufacturing outside the United States may also create exposure under 35 U.S.C. § 271(g) if a patented process is used and the resulting product is imported.
How does US 10,780,088 compare with composition and formulation patents?
| Protection type |
Product or conduct covered |
Generic vulnerability |
| Composition patent |
Talazoparib molecule |
Usually high barrier until expiration |
| Stereochemical patent |
(8S,9R) talazoparib |
Strong if commercial product uses that stereoisomer |
| US 10,780,088 |
Prostate-cancer treatment method |
Label-dependent and use-dependent |
| Formulation patent |
Specific dosage form or excipient system |
Avoidance may be possible through formulation redesign |
| Manufacturing patent |
Synthesis or intermediate process |
Alternative process may reduce risk |
| FDA exclusivity |
Approved indication or population |
Ends independently of patent expiry |
US 10,780,088 is less absolute than a composition-of-matter patent because infringement depends on the claimed therapeutic use. It can still be highly effective against a full-label generic for prostate cancer.
Key Takeaways
- US 10,780,088 covers talazoparib treatment of prostate cancer.
- Claim 1 is the principal broad claim and includes salts and solvates.
- Claim 9 separately targets the (8S,9R) active stereoisomer.
- The claims cover monotherapy and combinations with radiation or specified anticancer agents.
- The claims do not require a biomarker, metastatic disease, castration resistance, dose, route, or formulation.
- Enzalutamide may fall within the claimed “antiandrogen” category, but the issued claim language and prosecution history require confirmation.
- Talazoparib is a small molecule, so generic, not biosimilar, competition is expected.
- A full-label ANDA would face greater risk than a section viii carve-out.
- The patent is only one part of the Talzenna estate; composition, formulation, combination, manufacturing, and regulatory protections must be assessed together.
- The enforceable expiration date requires review of the USPTO patent-term record and any Orange Book listing.
FAQs About US Patent 10,780,088 and Talazoparib
Can a generic sell talazoparib for breast cancer while omitting prostate cancer?
Potentially. A section viii carve-out may permit marketing for an unpatented indication, but the label, promotional conduct, and remaining patented uses must be evaluated together.
Does claim 1 cover enzalutamide specifically?
Claim 1 covers talazoparib monotherapy and does not require a named combination partner. Enzalutamide may also be relevant to dependent claims that recite an antiandrogen, subject to claim construction.
Does changing the talazoparib dosage avoid the patent?
Not necessarily. Claims 1 and 9 do not specify a dose. A different dose could remain within the method claims if talazoparib is administered to treat prostate cancer.
Can a company avoid the patent by using a talazoparib solvate?
Claim 1 expressly includes pharmaceutically acceptable solvates. A solvate would not avoid claim 1 merely because it is a different physical form.
Does the patent block manufacturing talazoparib outside the United States?
Not automatically. The patent is primarily a treatment-method patent. Separate process claims and the importation provisions of U.S. patent law would determine manufacturing-related exposure.
References
- U.S. Food and Drug Administration. (2018). FDA approves talazoparib for deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. FDA.
- U.S. Food and Drug Administration. (2023). FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer. FDA.
- United States Patent and Trademark Office. (2020). U.S. Patent No. 10,780,088, methods of treating prostate cancer. U.S. Department of Commerce.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Code, Title 35, §§ 154, 156, 271. (2024). Patents. United States Code.
